Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects

Trial Profile

A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aravive S6 (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Aravive Biologics
  • Most Recent Events

    • 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    • 13 Nov 2018 Results presented in an Aravive Media Release.
    • 13 Nov 2018 According to an Aravive Biologics media release, detailed data were presented at at the Molecular Targets and Cancer Therapeutics 2018 EORTC-NCI-AACR Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top